FDA Issues Draft Guidance to Accelerate Individualized Therapies for Rare Diseases
Mar 21, 2026
The FDA has issued draft guidance creating a "Plausible Mechanism Framework" to accelerate approval of individualized therapies for ultra-rare diseases where traditional clinical trials are not feasible. The guidance focuses on gene editing and RNA-based treatments targeting specific genetic abnormalities.